Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Kazunari, Tateishi"'
Autor:
Ryota Ozawa, Kei Sonehara, Tsutomu Hachiya, Shuhei Nozawa, Toshihiko Agatsuma, Hiroshi Yamamoto, Akane Kato, Akemi Matsuo, Taro Hirabayashi, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Introduction Chemoimmunotherapy is widely used as the first‐line management of advanced non‐small cell lung cancer (NSCLC) in clinical settings. However, predictive factors associated with the development of immune‐related adverse even
Externí odkaz:
https://doaj.org/article/aa42099c35ad42f8a04023c3e61f282a
Autor:
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Background Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death‐ligand 1 (PD‐L1) expression is an important is
Externí odkaz:
https://doaj.org/article/9abe2da6e7c64c909348f0fdd32c3056
Autor:
Atsuhito Ushiki, Shunnosuke Tanaka, Miwa Yamanaka, Jumpei Akahane, Yuichi Ikuyama, Masamichi Komatsu, Kei Sonehara, Takashi Ichiyama, Yosuke Wada, Kazunari Tateishi, Yoshiaki Kitaguchi, Masayuki Hanaoka
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract Multidrug therapy for Mycobacterium avium complex pulmonary disease (MAC-PD) results in negative sputum cultures. However, the prognostic value of this treatment approach remains unclear. This study aimed to clarify whether multidrug therapy
Externí odkaz:
https://doaj.org/article/8849534b57b44145ac1feeb88c983c29
Autor:
Tatsuya Yazaki, Kei Sonehara, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masanori Yasuo, Masayuki Hanaoka
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 305-310 (2024)
Introduction: Primary tracheal adenoid cystic carcinoma (TACC) is a rare low-grade lung cancer of bronchial gland origin. Surgery is the first choice of treatment; however, in cases of recurrence or inoperability, a combination of radiation and chemo
Externí odkaz:
https://doaj.org/article/9c7586c3b9e24d4c93b14de76598dcfd
Autor:
Kei Sonehara, Shuhei Nozawa, Yusuke Suzuki, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 939-945 (2023)
Pulmonary spindle cell carcinoma is a subtype of pulmonary sarcomatoid carcinoma and a very rare tumor type with a poor prognosis. A few case reports have documented patients with pulmonary sarcomatoid carcinoma with anaplastic lymphoma kinase rearra
Externí odkaz:
https://doaj.org/article/10df2b21bccf4e508b48e51ede6a3312
Autor:
Kei Sonehara, Ryota Ozawa, Mineyuki Hama, Shuhei Nozawa, Toshihiko Agatsuma, Kenichi Nishie, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Thoracic Cancer, Vol 14, Iss 6, Pp 636-642 (2023)
Abstract Background Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination im
Externí odkaz:
https://doaj.org/article/9497c8b11ed347c9b0b471268d489d91
Autor:
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Satoshi Wasamoto, Shigeru Koyama, Fumiaki Yoshiike, Mineyuki Hama, Kenichi Nishie, Daichi Kondo, Toshihiko Agatsuma, Akane Kato, Munetake Takata, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 14, Pp 2031-2040 (2022)
Abstract Backgrounds The PACIFIC trial established durvalumab consolidation therapy after concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non–small cell lung cancer (LA‐NSCLC). However, little is known about the
Externí odkaz:
https://doaj.org/article/70885b62a3b64f34b89b53fcffcb92c5
Autor:
Ou Yamaguchi, Kyoichi Kaira, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Kazunari Tateishi, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Ichiei Kuji, Nobuhiko Seki
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Anti-programmed death-1 (PD-1) blockade is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, no appropriate modality exists for monitoring its therapeutic response immediately after initiation. Therefore, we aime
Externí odkaz:
https://doaj.org/article/17c72f5807b24ca8badaa7df4f5f909e
Autor:
Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu, Kei Sonehara, Shintaro Kanda, Masayuki Hanaoka, Tomonobu Koizumi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 7, Pp 1006-1013 (2022)
Abstract Background The prognostic implications of palliative chemotherapy for advanced or recurrent thymic carcinomas require full elucidation. The lung immune prognostic index (LIPI) is a novel prognostic index whose effectiveness has recently been
Externí odkaz:
https://doaj.org/article/abc11403913b4410b5ea7a691a0c635c
Autor:
Taisuke Araki, Yoshiaki Kitaguchi, Yusuke Suzuki, Masamichi Komatsu, Kei Sonehara, Yosuke Wada, Kazunari Tateishi, Masayuki Hanaoka
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2857-2864 (2021)
Abstract Background The quantity of skeletal muscles has recently been reported to have prognostic value in patients with non‐small‐cell lung cancer (NSCLC) treated with second‐line immunotherapy. However, the prognostic role of skeletal muscle
Externí odkaz:
https://doaj.org/article/3e4967d39c264ff78edb856a3797ef63